Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xomen-E5 filing

Executive Summary

Xoma submits PLA for monoclonal antibody-based product for treatment of gram negative sepsis, firm announced March 31. Xomen E-5, developed in conjunction with Pfizer, may be used to treat gram negative sepsis, which occurs "in patients who have undergone invasive surgery or trauma or in individuals whose immune systems are compromised." Pfizer will market the product worldwide; U.S. marketing will be handled by its Roerig division.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel